Autophagy

Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Virology, Company, National, Hematology, Glioblastoma, Neck, Cell death, Forward-looking statement, Immunotherapy, Legislation, WNK1, Adult, University of Calgary, Liver, Breast, AACR, SEC, Doctor of Philosophy, Research, Head, Immunogenic cell death, American Association, CT, Cancer, Dermatology, Tran, MD, Ophthalmology, Association, American Association for Cancer Research, Safety, NIH, University, ASCO, Cumming School of Medicine, GLOBE, Phosphorylation, Autophagy, Melanoma, Drug discovery, OTCQB, Microbiology, Lysine, Breast cancer, Patient, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Medical imaging

The University of Calgary team subsequently investigated target validation and modulation of PV-10 treatment on protein kinase signaling and associated impacts on specific oncogenic pathways in these adult solid tumor cancers.

Key Points: 
  • The University of Calgary team subsequently investigated target validation and modulation of PV-10 treatment on protein kinase signaling and associated impacts on specific oncogenic pathways in these adult solid tumor cancers.
  • WNK1 potentially regulates important oncogenic pathways, including Wnt signaling by controlling -catenin levels.
  • We are grateful to Dr. Narendran and his University of Calgary team for their many discoveries related to PV-10 cancer treatment, including now identifying multiple, specific, actionable drug targets.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes.

Casma Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 7, 2022
GLOBE, Patient, Autophagy, Therapy, Drug discovery, Protein, Organelle, Neurodegeneration, Lists of diseases, Conference, Casma, Arrest, Disease, Inflammation, Online gambling, Pharmaceutical industry

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma management will participate in virtual investor meetings on April 14, 2022 at the upcoming 21st Annual Needham Virtual Healthcare Conference being held on Monday, April 11 - Thursday, April 14, 2022.

Key Points: 
  • CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma management will participate in virtual investor meetings on April 14, 2022 at the upcoming 21st Annual Needham Virtual Healthcare Conference being held on Monday, April 11 - Thursday, April 14, 2022.
  • Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients.
  • The autophagy machinery targets larger and more complex disease targets such as organelles, protein aggregates and large signaling complexes and directs them to the lysosome for elimination.
  • By selectively degrading disease targets by autophagy, Casma expects to be able to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration and metabolic disorders.

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Inflammation, Cancer, Therapy, Genome, Lung, SCCL, AACR, American Association, Enzyme, Neoplasm, Cellular senescence, Immunity, Immune system, Association, American Association for Cancer Research, Biology, Autophagy, Patient, Disease, Pembrolizumab, Pharmaceutical industry, Vaccine, Medical imaging

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Companys lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Companys lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.
  • RBN-2397 is a small molecule inhibitor of PARP7 being evaluated in multiple clinical trials for the treatment of cancer.
  • RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Global Targeted Protein Degradation (TPD) Market Landscape Analysis 2022 by Technologies, Pipeline, Partnering and Financing - Focus on Proteasomal, Lysosomal & Autophagy Pathways - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 6, 2022
Health, Other Science, Clinical Trials, Pharmaceutical, Science, Biotechnology, PROTAC, Poster, NASDAQ, Partnering, 2021 Essex County Council election, Industry, Technology, Drug resistance, Autophagy, Bristol Myers Squibb, Acquisition, Merck, Amgen, Fine chemical, Pharmaceutical industry, Natural rubber, Silk, Proteasome, TPD, Bayer

The "Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing" report has been added to ResearchAndMarkets.com's offering.
  • This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022.
  • The average market capitalization of five NASDAQ listed TPD technology companies was US$ 1.5 bln as of March 4, 2022.
  • This report describes and analyzes the industry landscape of targeted protein degradation by proteasomal-, lysosomal- and autophagy-targeted technologies.

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Mitochondrion, Cancer, Therapy, Family, Large-cell lung carcinoma, Congress, DNA, Lung, Merck Group, Reactive oxygen species, Cell death, Trial of the century, CRADA, ICD, Growth, Organelle, AACR, Immunogenic cell death, Doctor of Philosophy, Caspase, Research, B cell, Tumor microenvironment, Development of the human body, Damage-associated molecular pattern, NSCLC, Multiple myeloma, Safety, DAMP, Prostate cancer, Merck Serono, CST, Thymoma, American Academy, Autophagy, César Award for Best Poster, ESMO, ASH, Necroptosis, NCI, PD-L1, University, Patient, Pharmaceutical industry, Vaccine, Platinum

"The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.

Key Points: 
  • "The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.
  • Sensitivity to PT-112 was assessed in human prostate cancer cell lines and the non-tumorigenic prostate cell line RWPE-1.
  • Key findings of the study included the following:
    PT-112 caused growth inhibition and cancer cell death without affecting healthy RWPE-1 cells.
  • Caspase inhibition reduced PT-112-induced cell death, with more mild effects seen with necroptosis inhibition, suggesting that cell death is primarily apoptotic.

Pancreatic Cancer Cells Harness Normal Tissue Turnover to Build Protective Barriers

Retrieved on: 
Monday, April 4, 2022
LaRue, Therapy, New York University Grossman School of Medicine, NYU Langone Health, Pancreatic cancer, Metabolism, NYU, Nutrient, SU2C, Malignancy, Biochemistry, GOT1, Growth, Arginine, Coronavirus Scientific Advisory Board (Turkey), KRAS, RNS, Lustgarten Foundation for Pancreatic Cancer Research, Pharmacology, Division, Doctor of Philosophy, Environment, Pancreatic tumor, Science, National Institutes of Health, National Academies of Sciences, Engineering, and Medicine, Neoplasm, Nitric oxide synthase 2 (inducible), Ultimate tensile strength, Cancer, National academy, Macrophage, Reactive nitrogen species, National, Radiation therapy, Autophagy, Kimmelman, Animal, Department, Enzyme, Protein, MRC1, Wound healing, Collagen, Medical imaging, Dietary supplement, Pharmaceutical industry

Past studies have shown that immune cells called macrophages contribute to a process called desmoplasia, which is caused by the abnormal turnover and excessive deposition of collagen that insulates pancreatic cancers.

Key Points: 
  • Past studies have shown that immune cells called macrophages contribute to a process called desmoplasia, which is caused by the abnormal turnover and excessive deposition of collagen that insulates pancreatic cancers.
  • This, in turn, caused neighboring, supportive stellate cells to build collagen-based meshes around tumors, say the study authors.
  • "Our results revealed how pancreatic tumors program macrophages to contribute to the construction of fibrotic barriers," says first study author Madeleine LaRue, PhD.
  • Pancreatic cancer remains difficult to treat in large part due to the extensive network of fibrotic tissue around tumors.

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

Retrieved on: 
Thursday, March 24, 2022
Therapy, Family, Weill Cornell Medicine, Yale School of Medicine, NEW, Lung, Merck Group, ICD, Cell death, Trial of the century, CRADA, University, Education, Yale school, Research, Doctor of Philosophy, Immunogenic cell death, Publication, United States Air Force Scientific Advisory Board, Gustave Roussy, Cancer, Weill Cornell Medical College in Qatar, Assistant, Cell biology, Radiation therapy, Merck Serono, European Academy of Management, Drug resistance, Autophagy, Department, NCI, Publishing, Toxicity, Pharmaceutical industry, Medical imaging, Vaccine, Medicine, Dermatology

NEW YORK, March 24, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Lorenzo Galluzzi, PhD, to the company's Scientific Advisory Board. Dr. Galluzzi leads the Galluzzi Lab at Weill Cornell Medical College in New York and is engaged in the development of the company's small molecule immunotherapy, PT-112, a potent immunogenic cancer cell death (ICD) inducer. Dr. Galluzzi is a highly-experienced leader in oncology research, teaching at top universities in the US and Europe and publishing extensively in scientific journals worldwide, with over 500 publications to date.

Key Points: 
  • Dr. Galluzzi leads the Galluzzi Lab at Weill Cornell Medical College in New York and is engaged in the development of the company's small molecule immunotherapy, PT-112, a potent immunogenic cancer cell death (ICD) inducer.
  • "We are excited for this new phase in our relationship with Dr. Galluzzi, who is world renowned for his research in immunogenic cell death in the field of oncology," said Phosplatin President and Chief Executive Officer Robert Fallon.
  • That study was published in a 2020 OncoImmunology paper titled "PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models."
  • The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism.

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

Retrieved on: 
Wednesday, March 16, 2022
RGCB, SEC, Time, Autophagy, Hepatocellular carcinoma, Technology, Liver, Liver cancer, Patient, Apoptosis, Partnership, Hep G2, BioMed Central, HCC, Lupus, Cardiovascular disease, Sorafenib, National Data Sharing and Accessibility Policy – Government of India, Regulation, Forward-looking statement, Food and Drug Administration Amendments Act of 2007, OTCQB, Orphan drug, Neoplasm, Patent, Ageing, Rajiv Gandhi Centre for Biotechnology, Cell, Oklahoma Medical Research Foundation, Food, Scientific Reports, Cancer, Incidence, Research, Biomedical Research, Death, Securities Exchange Act of 1934, Drug Quality and Security Act, Securities Act of 1933, Mouse, OMRF, Frontiers, Pharmaceutical industry, Dietary supplement, Biotechnology

NEW YORK, March 16, 2022 /PRNewswire/ --Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ --Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.
  • Denis Corin, Q BioMed CEO, said, "Having successfully completed a very challenging synthesis program, we are now finalizing manufacturing for tox studies.
  • Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
  • Q BioMed has the exclusive license to the technology through an agreement with RGCB and the Oklahoma Medical Research Foundation.

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
MSD, Priority review, Apoptosis, Drug resistance, BTD, AACR, American Association for Cancer Research, Center for Drug Evaluation and Research, Infection, CDE, CHB, FTD, H3K27me3, Research, Therapy, FAK, Unity Biotechnology, Degenerative disease, Stock exchange, AstraZeneca, Mutation, MD Anderson Cancer Center, National Medical Products Administration, KRAS, Multimedia, NMPA, IAP, Cancer, Mesothelioma, Motherboard, EED, Dana–Farber Cancer Institute, Patient, Treatment, TKI, California Department of Alcohol and Drug Programs, American Association, TP53, 2021 Essex County Council election, Center, Autophagy, Hepatitis, GDP, Mayo Clinic, Biotechnology, CML, Association, ODD, The Pauly D Project, Pharmaceutical industry, Fine chemical, Communications satellite, Potash, EU, Pfizer

The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.

Key Points: 
  • The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.
  • This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
  • These six abstracts from Ascentage Pharma include:
    Time: 9:00 AM 12:30 PM CST, April 13, 2022
    BCL-2 mutation is a key mechanism driving the drug-resistance to BCL-2 inhibitors.
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.

Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease

Retrieved on: 
Thursday, February 10, 2022
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, UK Biobank, Patient, GYS2, Tissue, Biomarker, Autophagy, Data science, Cardiac muscle, HIV disease progression rates, Biobank, Enzyme replacement therapy, Therapy, Technology, Lists of diseases, Cell, Kingdom, LinkedIn, Compass, Twitter, Glycogen, Disease, Research, Glycogen storage disease type II, Weakness, Program, Translation, Caregiver, Toxicity, Gene, GAA, Pharmaceutical industry, Vaccine, Medical imaging, Maze, PPP1R3A

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1).

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1).
  • Pompe disease affects both people who are living with the disease, as well as their caregivers.
  • This work demonstrates the potential value of our substrate reduction approach across the Pompe disease spectrum both as combination therapy and as monotherapy.
  • Taken together, the preclinical data support the potential for a GYS1 inhibitor, such as MZE001, as a treatment for Pompe disease.